<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="of direct acting agents for emerging needed therapy against severe" exact="acute" post="respiratory syndrome coronavirus-2 WangSheng-FanabcChenKuan-HsuanadWangSzu-YuaYarmishynAliaksandr A.eLaiWei-YiceLinYi-YingceWangMong-LienefgChouShih-JieceYangYi-PingcegChangYuh-Lihacd*[a], [b], [c], [d], [e],"/>
 <result pre="direct acting agents for emerging needed therapy against severe acute" exact="respiratory" post="syndrome coronavirus-2 WangSheng-FanabcChenKuan-HsuanadWangSzu-YuaYarmishynAliaksandr A.eLaiWei-YiceLinYi-YingceWangMong-LienefgChouShih-JieceYangYi-PingcegChangYuh-Lihacd*[a], [b], [c], [d], [e], [f],"/>
 <result pre="acting agents for emerging needed therapy against severe acute respiratory" exact="syndrome" post="coronavirus-2 WangSheng-FanabcChenKuan-HsuanadWangSzu-YuaYarmishynAliaksandr A.eLaiWei-YiceLinYi-YingceWangMong-LienefgChouShih-JieceYangYi-PingcegChangYuh-Lihacd*[a], [b], [c], [d], [e], [f], [g],"/>
 <result pre="[g], *Address Correspondence: Dr. Yuh-Lih Chang, Pharmacy Department, Taipei Veterans" exact="General" post="Hospital, 201, Section 2, Shi-Pai Road, Taipei 112, Taiwan,"/>
 <result pre="PMC, consistent with existing copyright protections.ca9-83-712.pdf Abstract Recently, the severe" exact="acute" post="respiratory syndrome coronavirus-2 (SARS-CoV-2) was quickly identified as the"/>
 <result pre="consistent with existing copyright protections.ca9-83-712.pdf Abstract Recently, the severe acute" exact="respiratory" post="syndrome coronavirus-2 (SARS-CoV-2) was quickly identified as the causal"/>
 <result pre="with existing copyright protections.ca9-83-712.pdf Abstract Recently, the severe acute respiratory" exact="syndrome" post="coronavirus-2 (SARS-CoV-2) was quickly identified as the causal pathogen"/>
 <result pre="of SARS-like illness all over the world. As the SARS-CoV-2" exact="infection" post="pandemic proceeds, many efforts are being dedicated to the"/>
 <result pre="virus, such as interferon, RNA-dependent RNA polymerase inhibitors, protease inhibitors," exact="viral" post="entry blockers, neuraminidase inhibitor, vaccine, antibody agent targeting the"/>
 <result pre="COVID-19 Direct therapy Pharmacological development SARS-CoV-2 1. Introduction The severe" exact="acute" post="respiratory syndrome coronavirus-2 (SARS-CoV-2) was quickly confirmed as the"/>
 <result pre="Direct therapy Pharmacological development SARS-CoV-2 1. Introduction The severe acute" exact="respiratory" post="syndrome coronavirus-2 (SARS-CoV-2) was quickly confirmed as the causal"/>
 <result pre="therapy Pharmacological development SARS-CoV-2 1. Introduction The severe acute respiratory" exact="syndrome" post="coronavirus-2 (SARS-CoV-2) was quickly confirmed as the causal pathogen"/>
 <result pre="leading to the outbreak of SARS-like illness (later named coronavirus" exact="disease" post="2019 [COVID-19]) in China.1 As for now, COVID-19 has"/>
 <result pre="genus of coronaviruses (CoVs) that are known to cause multiple" exact="respiratory" post="infections in humans. The history of CoVs can trace"/>
 <result pre="of coronaviruses (CoVs) that are known to cause multiple respiratory" exact="infections" post="in humans. The history of CoVs can trace back"/>
 <result pre="proteins that are involved in genome replication and transcription. The" exact="viral" post="membrane harbors the S protein that plays an important"/>
 <result pre="and is responsible for inducing host immune response.3 The CoV" exact="infection" post="begins with the interaction of the receptor binding domain"/>
 <result pre="the interaction of the receptor binding domain (RBD) of the" exact="viral" post="S protein and the receptor on the cell surface"/>
 <result pre="as interferon (IFN), RdRp inhibitors, protease inhibitors, coronaviral protease inhibitor," exact="viral" post="entry blocker, neuraminidase inhibitor, vaccine, antibody, agent targeting the"/>
 <result pre="as IFNs and ribavirin that have been used for other" exact="viral" post="infections or other indications is usually employed. These drugs"/>
 <result pre="IFNs and ribavirin that have been used for other viral" exact="infections" post="or other indications is usually employed. These drugs have"/>
 <result pre="novel specific anti-SARS-CoV-2 agents might comprise inhibitors interfering with the" exact="viral" post="replication cycle, antibody targeting the host receptor and virus"/>
 <result pre="group of cytokine mediators that are induced in response to" exact="virus infection." post="IFNs are classified into subtypes I and II, both"/>
 <result pre="mRNA translation inhibition, enhancement of RNA degradation, RNA editing, targeting" exact="viral" post="nucleocapsids, and inhibiting RNA synthesis.6 Among the type I"/>
 <result pre="editing, targeting viral nucleocapsids, and inhibiting RNA synthesis.6 Among the" exact="type I" post="IFN, IFN-Î± is quickly stimulated in innate immune response"/>
 <result pre="IFN-Î± is quickly stimulated in innate immune response to initial" exact="virus infection." post="IFN-Î± and Î² inhibit the replication of SARS-CoV.7,8 However,"/>
 <result pre="innate immunity against SARS-CoV.10 Pegylated IFN-Î±2b, a licensed drug for" exact="chronic hepatitis" post="B and C, showed the anti-SARS-CoV activity by decreasing"/>
 <result pre="immunity against SARS-CoV.10 Pegylated IFN-Î±2b, a licensed drug for chronic" exact="hepatitis" post="B and C, showed the anti-SARS-CoV activity by decreasing"/>
 <result pre="hepatitis B and C, showed the anti-SARS-CoV activity by decreasing" exact="viral" post="replication and lung damage.11,12 IFN-Î± is a candidate medication"/>
 <result pre="a broad-spectrum antiviral agent that has previously been used for" exact="hepatitis C" post="patients treatment. It is a guanosine derivative and can"/>
 <result pre="and can target RdRp enzyme to inhibit the synthesis of" exact="viral" post="RNA and capping of mRNA. During the previous SARS"/>
 <result pre="animal and human cell lines.7 Regarding the adverse reactions and" exact="absence of" post="the in vitro efficacy for SARS-CoV, the usage of"/>
 <result pre="to adenosine, it can inhibit the RdRp by incorporating into" exact="viral" post="RNA, thus halting viral genome replication. Recently, the first"/>
 <result pre="inhibit the RdRp by incorporating into viral RNA, thus halting" exact="viral" post="genome replication. Recently, the first experience of remdesivir usage"/>
 <result pre="can bind to HIV-1 protease and block the cleavage of" exact="viral" post="Gag-Pol precursor polyprotein into specific proteins essential for HIV"/>
 <result pre="of viral Gag-Pol precursor polyprotein into specific proteins essential for" exact="HIV infection," post="resulting in dysfunctional viral particles. Another component, ritonavir, can"/>
 <result pre="into specific proteins essential for HIV infection, resulting in dysfunctional" exact="viral" post="particles. Another component, ritonavir, can increase the plasma level"/>
 <result pre="In addition, nelfinavir has revealed rational binding conformation with the" exact="viral" post="main protease of SARS-CoV-2. (BioRxiv doi:10.1101/2020.01.28.922922.) Therefore, nelfinavir might"/>
 <result pre="proteases, chymotrypsin-like and papain-like proteases, which are responsible for the" exact="viral" post="replication and interfering with the host innate immunity. Hence,"/>
 <result pre="candidate targets for developing new drugs to fight COVID-19. 2.5." exact="Viral" post="entry inhibitors Hydroxychloroquine and chloroquine are aminoquinolines, which have"/>
 <result pre="and chloroquine are aminoquinolines, which have been used to treat" exact="autoimmune diseases" post="and malaria. They are weak diprotic bases that can"/>
 <result pre="elevate the pH of the endosomes, which in turn prevent" exact="viral" post="entry fusion.35 Chloroquine can also interfere with ACE2 glycosylation"/>
 <result pre="and SARS-CoV-2. In vitro tests revealed its capability to reduce" exact="viral" post="copy number. Its in vivo antiviral capability is now"/>
 <result pre="identification of novel small molecules which can bind to the" exact="viral" post="S protein or S proteinâ€&quot;human ACE2 interface has been"/>
 <result pre="(TMPRSS2).37 Hence, camostat mesylate, a TMPRSS2 inhibitor, can eliminate SARS-CoV-2" exact="infection" post="in vitro assay. On the other hand, the heptad"/>
 <result pre="SARS-CoV-2 S protein is also involved in the process of" exact="viral" post="entry.38 Moreover, anti-HR peptides possess anti-SARS-CoV-2 activity through inhibition"/>
 <result pre="entry.38 Moreover, anti-HR peptides possess anti-SARS-CoV-2 activity through inhibition of" exact="viral" post="fusion.38 The pH- and receptor-dependent endocytosis are also involved"/>
 <result pre="coronaviruses should be carefully interpreted.44 Amantadine, indicated for influenza and" exact="Parkinson" post="disease, has showed the antiviral activity against human coronavirus"/>
 <result pre="2.8. Vaccine Effective vaccines are important to prevent and control" exact="viral" post="pandemics such as influenza vaccines. Unfortunately, even after numerous"/>
 <result pre="cage nanoparticles, which are innate immunomodulators, exhibit high anti-SARS-CoV potency.50,51" exact="Protein" post="cage nanoparticles designed vaccine for SARS-CoV might be further"/>
 <result pre="acid-based vaccine, adenoviral vector-based vaccine, recombinant subunits vaccine, recombinant influenza" exact="viral" post="vector vaccine, inactivated vaccine, and so on.53 Upon current"/>
 <result pre="SARS-CoV-2 virus, might inhibit the virus replication and mitigate the" exact="disease" post="severity. According to the prior experience in treating MERS,"/>
 <result pre="the prior experience in treating MERS, SARS, Ebola, and influenza" exact="viral" post="infections with convalescent plasma from recovered patients that contains"/>
 <result pre="prior experience in treating MERS, SARS, Ebola, and influenza viral" exact="infections" post="with convalescent plasma from recovered patients that contains high"/>
 <result pre="high antibody titers against virus, convalescent plasma could ameliorate the" exact="viral" post="level and mortality.54â€&quot;57 However, the challenges such as unknown"/>
 <result pre="viral level and mortality.54â€&quot;57 However, the challenges such as unknown" exact="viral" post="kinetics of SARS-CoV-2 and insufficient donors with suitable clinical"/>
 <result pre="clinical status still exist. The usage of monoclonal antibodies for" exact="infectious disease" post="is a new area, which addresses many concerns related"/>
 <result pre="status still exist. The usage of monoclonal antibodies for infectious" exact="disease" post="is a new area, which addresses many concerns related"/>
 <result pre="domains on the S2 fragment of SARS-CoV-2 are involved in" exact="viral" post="entry mechanism.38 Furthermore, ultimately, the cocktail antibodies strategy might"/>
 <result pre="Beyond targeting the S protein of SARS-CoV-2, directly targeting the" exact="viral" post="RNA genome through inducing its degradation might be a"/>
 <result pre="of several inflammatory factors, dendritic cell maturation, and synthesis of" exact="type I" post="IFNs which can control the viral spread and eliminate"/>
 <result pre="and synthesis of type I IFNs which can control the" exact="viral" post="spread and eliminate virus via phagocytosis by macrophages.66 Learning"/>
 <result pre="Celularity, a New Jersey-based therapeutics company declared that, â€œCYNK-001, a" exact="cancer" post="treatment is under clinical trial against COVID-19 awaiting for"/>
 <result pre="for FDA permission.â€� However, several challenges exist such as novel" exact="viral" post="evading mechanisms of immune system including N protein of"/>
 <result pre="such as influenza, HIV, dengue virus, West Nile virus, and" exact="Venezuelan equine encephalitis" post="virus in vitro.69â€&quot;72 Initially, the inhibitory activity of ivermectin"/>
 <result pre="influenza, HIV, dengue virus, West Nile virus, and Venezuelan equine" exact="encephalitis" post="virus in vitro.69â€&quot;72 Initially, the inhibitory activity of ivermectin"/>
 <result pre="in a signal-dependent SARS-CoV nucleocapsid protein nucleocytoplasmic trafficking during SARS-CoV" exact="infection" post="and could affect host cell division.76â€&quot;80 Besides, the SARS-CoV"/>
 <result pre="and clinical characteristics of 99 cases of 2019 novel coronavirus" exact="pneumonia" post="in Wuhan, China: a descriptive study.Lancet2020;395:507â€&quot;13.32007143 2.PillaiyarTMeenakshisundaramSManickamMRecent discovery and"/>
 <result pre="immune activation.J Gen Virol2009;90Pt 112686â€&quot;94.19625461 11.HaagmansBLKuikenTMartinaBEFouchierRARimmelzwaanGFvan AmerongenGet al.Pegylated interferon-alpha protects" exact="type 1" post="pneumocytes against SARS coronavirus infection in macaques.Nat Med2004;10:290â€&quot;3.14981511 12.BijlengaGProposal"/>
 <result pre="AmerongenGet al.Pegylated interferon-alpha protects type 1 pneumocytes against SARS coronavirus" exact="infection" post="in macaques.Nat Med2004;10:290â€&quot;3.14981511 12.BijlengaGProposal for vaccination against SARS coronavirus"/>
 <result pre="macaques.Nat Med2004;10:290â€&quot;3.14981511 12.BijlengaGProposal for vaccination against SARS coronavirus using avian" exact="infectious" post="bronchitis virus strain H from The Netherlands.J Infect2005;51:263â€&quot;5. 13.LoutfyMRBlattLMSiminovitchKAWardSWolffBLhoHet"/>
 <result pre="Med2004;10:290â€&quot;3.14981511 12.BijlengaGProposal for vaccination against SARS coronavirus using avian infectious" exact="bronchitis" post="virus strain H from The Netherlands.J Infect2005;51:263â€&quot;5. 13.LoutfyMRBlattLMSiminovitchKAWardSWolffBLhoHet al.Interferon"/>
 <result pre="The Netherlands.J Infect2005;51:263â€&quot;5. 13.LoutfyMRBlattLMSiminovitchKAWardSWolffBLhoHet al.Interferon alfacon-1 plus corticosteroids in severe" exact="acute" post="respiratory syndrome: a preliminary study.JAMA2003;290:3222â€&quot;8.14693875 14.MustafaSBalkhyHGabereMNCurrent treatment options and"/>
 <result pre="Netherlands.J Infect2005;51:263â€&quot;5. 13.LoutfyMRBlattLMSiminovitchKAWardSWolffBLhoHet al.Interferon alfacon-1 plus corticosteroids in severe acute" exact="respiratory" post="syndrome: a preliminary study.JAMA2003;290:3222â€&quot;8.14693875 14.MustafaSBalkhyHGabereMNCurrent treatment options and the"/>
 <result pre="role of peptides as potential therapeutic components for Middle East" exact="Respiratory" post="Syndrome (MERS): a review.J Infect Public Health2018;11:9â€&quot;17.28864360 15.WenzelRPEdmondMBManaging SARS"/>
 <result pre="of peptides as potential therapeutic components for Middle East Respiratory" exact="Syndrome" post="(MERS): a review.J Infect Public Health2018;11:9â€&quot;17.28864360 15.WenzelRPEdmondMBManaging SARS amidst"/>
 <result pre="amidst uncertainty.N Engl J Med2003;348:1947â€&quot;8.12748313 16.TanELOoiEELinCYTanHCLingAELimBet al.Inhibition of SARS coronavirus" exact="infection" post="in vitro with clinically approved antiviral drugs.Emerg Infect Dis2004;10:581â€&quot;6.15200845"/>
 <result pre="against influenza virus.Antimicrob Agents Chemother2005;49:981â€&quot;6.15728892 23.GronebergDAPoutanenSMLowDELodeHWelteTZabelPTreatment and vaccines for severe" exact="acute" post="respiratory syndrome.Lancet Infect Dis2005;5:147â€&quot;55.15766649 24.ChanJFYaoYYeungMLDengWBaoLJiaLet al.Treatment with lopinavir/ritonavir or"/>
 <result pre="influenza virus.Antimicrob Agents Chemother2005;49:981â€&quot;6.15728892 23.GronebergDAPoutanenSMLowDELodeHWelteTZabelPTreatment and vaccines for severe acute" exact="respiratory" post="syndrome.Lancet Infect Dis2005;5:147â€&quot;55.15766649 24.ChanJFYaoYYeungMLDengWBaoLJiaLet al.Treatment with lopinavir/ritonavir or interferon-Î²1b"/>
 <result pre="24.ChanJFYaoYYeungMLDengWBaoLJiaLet al.Treatment with lopinavir/ritonavir or interferon-Î²1b improves outcome of MERS-CoV" exact="infection" post="in a Nonhuman Primate Model of Common Marmoset.J Infect"/>
 <result pre="of the index patient who caused tertiary transmission of coronavirus" exact="disease" post="2019 in Korea: the application of lopinavir/ritonavir for the"/>
 <result pre="Korea: the application of lopinavir/ritonavir for the treatment of COVID-19" exact="pneumonia" post="monitored by quantitative RT-PCR.J Korean Med Sci2020;35:e89.32080993 27.YoungBEOngSWXKalimuddinSLowJGTanSYLohJet al.Epidemiologic"/>
 <result pre="and therapeutic procedure for four cases with 2019 novel coronavirus" exact="pneumonia" post="receiving combined Chinese and Western medicine treatment.Biosci Trends2020;14:64â€&quot;8.32037389 29.CaoBWangYWenDLiuWWangJFanGet"/>
 <result pre="31.ParkJYJeongHJKimJHKimYMParkSJKimDet al.Diarylheptanoids from Alnus japonica inhibit papain-like protease of severe" exact="acute" post="respiratory syndrome coronavirus.Biol Pharm Bull2012;35:2036â€&quot;42.22971649 32.ChenLGuiCLuoXYangQGÃ¼ntherSScandellaEet al.Cinanserin is an"/>
 <result pre="al.Diarylheptanoids from Alnus japonica inhibit papain-like protease of severe acute" exact="respiratory" post="syndrome coronavirus.Biol Pharm Bull2012;35:2036â€&quot;42.22971649 32.ChenLGuiCLuoXYangQGÃ¼ntherSScandellaEet al.Cinanserin is an inhibitor"/>
 <result pre="from Alnus japonica inhibit papain-like protease of severe acute respiratory" exact="syndrome" post="coronavirus.Biol Pharm Bull2012;35:2036â€&quot;42.22971649 32.ChenLGuiCLuoXYangQGÃ¼ntherSScandellaEet al.Cinanserin is an inhibitor of"/>
 <result pre="al.Cinanserin is an inhibitor of the 3C-like proteinase of severe" exact="acute" post="respiratory syndrome coronavirus and strongly reduces virus replication in"/>
 <result pre="is an inhibitor of the 3C-like proteinase of severe acute" exact="respiratory" post="syndrome coronavirus and strongly reduces virus replication in vitro.J"/>
 <result pre="an inhibitor of the 3C-like proteinase of severe acute respiratory" exact="syndrome" post="coronavirus and strongly reduces virus replication in vitro.J Virol2005;79:7095â€&quot;103.15890949"/>
 <result pre="spike protein.Cell Mol Immunol20201â€&quot;3doi: 10.1038/s41423-020-0374-231611651 39.InoueYTanakaNTanakaYInoueSMoritaKZhuangMet al.Clathrin-dependent entry of severe" exact="acute" post="respiratory syndrome coronavirus into target cells expressing ACE2 with"/>
 <result pre="protein.Cell Mol Immunol20201â€&quot;3doi: 10.1038/s41423-020-0374-231611651 39.InoueYTanakaNTanakaYInoueSMoritaKZhuangMet al.Clathrin-dependent entry of severe acute" exact="respiratory" post="syndrome coronavirus into target cells expressing ACE2 with the"/>
 <result pre="Mol Immunol20201â€&quot;3doi: 10.1038/s41423-020-0374-231611651 39.InoueYTanakaNTanakaYInoueSMoritaKZhuangMet al.Clathrin-dependent entry of severe acute respiratory" exact="syndrome" post="coronavirus into target cells expressing ACE2 with the cytoplasmic"/>
 <result pre="Res2008;18:290â€&quot;301.18227861 41.NeveuGZiv-AvABarouch-BentovRBerkermanEMulhollandJEinavSAP-2-associated protein kinase 1 and cyclin G-associated kinase regulate" exact="hepatitis C" post="virus entry and are potential drug targets.J Virol2015;89:4387â€&quot;404.25653444 42.RichardsonPGriffinITuckerCSmithDOechsleOPhelanAet"/>
 <result pre="drug targets.J Virol2015;89:4387â€&quot;404.25653444 42.RichardsonPGriffinITuckerCSmithDOechsleOPhelanAet al.Baricitinib as potential treatment for 2019-nCoV" exact="acute" post="respiratory disease.Lancet2020;395:e30â€&quot;1.32032529 43.HuangCWangYLiXRenLZhaoJHuYet al.Clinical features of patients infected with"/>
 <result pre="targets.J Virol2015;89:4387â€&quot;404.25653444 42.RichardsonPGriffinITuckerCSmithDOechsleOPhelanAet al.Baricitinib as potential treatment for 2019-nCoV acute" exact="respiratory" post="disease.Lancet2020;395:e30â€&quot;1.32032529 43.HuangCWangYLiXRenLZhaoJHuYet al.Clinical features of patients infected with 2019"/>
 <result pre="patients infected with 2019 novel coronavirus in Wuhan, China.Lancet2020;395:497â€&quot;506.31986264 44.McCrearyEKPogueJMCoronavirus" exact="Disease" post="2019 Treatment: A Review of Early and Emerging Options.Open"/>
 <result pre="treatment with neuroprotective and antiviral properties against a neuroinvasive human" exact="respiratory" post="virus.J Virol2014;88:1548â€&quot;63.24227863 46.AndersonPOBreastfeeding and respiratory antivirals: coronavirus and influenza.Breastfeed"/>
 <result pre="properties against a neuroinvasive human respiratory virus.J Virol2014;88:1548â€&quot;63.24227863 46.AndersonPOBreastfeeding and" exact="respiratory" post="antivirals: coronavirus and influenza.Breastfeed Med2020;15:128.32129667 47.WrappDWangNCorbettKSGoldsmithJAHsiehCLAbionaOet al.Cryo-EM structure of"/>
 <result pre="al.Rhesus theta-defensin prevents death in a mouse model of severe" exact="acute" post="respiratory syndrome coronavirus pulmonary disease.J Virol2009;83:11385â€&quot;90.19710146 51.WileyJARichertLESwainSDHarmsenABarnardDLRandallTDet al.Inducible bronchus-associated"/>
 <result pre="theta-defensin prevents death in a mouse model of severe acute" exact="respiratory" post="syndrome coronavirus pulmonary disease.J Virol2009;83:11385â€&quot;90.19710146 51.WileyJARichertLESwainSDHarmsenABarnardDLRandallTDet al.Inducible bronchus-associated lymphoid"/>
 <result pre="prevents death in a mouse model of severe acute respiratory" exact="syndrome" post="coronavirus pulmonary disease.J Virol2009;83:11385â€&quot;90.19710146 51.WileyJARichertLESwainSDHarmsenABarnardDLRandallTDet al.Inducible bronchus-associated lymphoid tissue"/>
 <result pre="in a mouse model of severe acute respiratory syndrome coronavirus" exact="pulmonary" post="disease.J Virol2009;83:11385â€&quot;90.19710146 51.WileyJARichertLESwainSDHarmsenABarnardDLRandallTDet al.Inducible bronchus-associated lymphoid tissue elicited by"/>
 <result pre="a protein cage nanoparticle enhances protection in mice against diverse" exact="respiratory" post="viruses.PLoS One2009;4:e7142.19774076 52.JacksonNACKesterKECasimiroDGurunathanSDeRosaFThe promise of mRNA vaccines: a biotech"/>
 <result pre="(Suppl 1:S18â€&quot;23.9988160 55.YehKMChiuehTSSiuLKLinJCChanPKPengMYet al.Experience of using convalescent plasma for severe" exact="acute" post="respiratory syndrome among healthcare workers in a Taiwan hospital.J"/>
 <result pre="1:S18â€&quot;23.9988160 55.YehKMChiuehTSSiuLKLinJCChanPKPengMYet al.Experience of using convalescent plasma for severe acute" exact="respiratory" post="syndrome among healthcare workers in a Taiwan hospital.J Antimicrob"/>
 <result pre="55.YehKMChiuehTSSiuLKLinJCChanPKPengMYet al.Experience of using convalescent plasma for severe acute respiratory" exact="syndrome" post="among healthcare workers in a Taiwan hospital.J Antimicrob Chemother2005;56:919â€&quot;22.16183666"/>
 <result pre="convalescent plasma and hyperimmune immunoglobulin for the treatment of severe" exact="acute" post="respiratory infections of viral etiology: a systematic review and"/>
 <result pre="plasma and hyperimmune immunoglobulin for the treatment of severe acute" exact="respiratory" post="infections of viral etiology: a systematic review and exploratory"/>
 <result pre="and hyperimmune immunoglobulin for the treatment of severe acute respiratory" exact="infections" post="of viral etiology: a systematic review and exploratory meta-analysis.J"/>
 <result pre="immunoglobulin for the treatment of severe acute respiratory infections of" exact="viral" post="etiology: a systematic review and exploratory meta-analysis.J Infect Dis2015;211:80â€&quot;90.25030060"/>
 <result pre="alter capsid protein distribution in mammalian cells and reduce Venezuelan" exact="Equine" post="Encephalitis virus replication.Antiviral Res2013;100:662â€&quot;72.24161512 71.TayMYFraserJEChanWKMorelandNJRathoreAPWangCet al.Nuclear localization of dengue"/>
 <result pre="capsid protein distribution in mammalian cells and reduce Venezuelan Equine" exact="Encephalitis" post="virus replication.Antiviral Res2013;100:662â€&quot;72.24161512 71.TayMYFraserJEChanWKMorelandNJRathoreAPWangCet al.Nuclear localization of dengue virus"/>
 <result pre="nuclear transport.Curr Opin Cell Biol2019;58:50â€&quot;60.30826604 76.RowlandRRChauhanVFangYPekoszAKerriganMBurtonMDIntracellular localization of the severe" exact="acute" post="respiratory syndrome coronavirus nucleocapsid protein: absence of nucleolar accumulation"/>
 <result pre="transport.Curr Opin Cell Biol2019;58:50â€&quot;60.30826604 76.RowlandRRChauhanVFangYPekoszAKerriganMBurtonMDIntracellular localization of the severe acute" exact="respiratory" post="syndrome coronavirus nucleocapsid protein: absence of nucleolar accumulation during"/>
 <result pre="Opin Cell Biol2019;58:50â€&quot;60.30826604 76.RowlandRRChauhanVFangYPekoszAKerriganMBurtonMDIntracellular localization of the severe acute respiratory" exact="syndrome" post="coronavirus nucleocapsid protein: absence of nucleolar accumulation during infection"/>
 <result pre="localization of the severe acute respiratory syndrome coronavirus nucleocapsid protein:" exact="absence of" post="nucleolar accumulation during infection and after expression as a"/>
 <result pre="respiratory syndrome coronavirus nucleocapsid protein: absence of nucleolar accumulation during" exact="infection" post="and after expression as a recombinant protein in vero"/>
 <result pre="the protein may disrupt host cell division.J Virol2001;75:9345â€&quot;56.11533198 80.HiscoxJAWurmTWilsonLBrittonPCavanaghDBrooksGThe coronavirus" exact="infectious" post="bronchitis virus nucleoprotein localizes to the nucleolus.J Virol2001;75:506â€&quot;12.11119619 81.FriemanMYountBHeiseMKopecky-BrombergSAPalesePBaricRSSevere"/>
 <result pre="protein may disrupt host cell division.J Virol2001;75:9345â€&quot;56.11533198 80.HiscoxJAWurmTWilsonLBrittonPCavanaghDBrooksGThe coronavirus infectious" exact="bronchitis" post="virus nucleoprotein localizes to the nucleolus.J Virol2001;75:506â€&quot;12.11119619 81.FriemanMYountBHeiseMKopecky-BrombergSAPalesePBaricRSSevere acute"/>
 <result pre="infectious bronchitis virus nucleoprotein localizes to the nucleolus.J Virol2001;75:506â€&quot;12.11119619 81.FriemanMYountBHeiseMKopecky-BrombergSAPalesePBaricRSSevere" exact="acute" post="respiratory syndrome coronavirus ORF6 antagonizes STAT1 function by sequestering"/>
 <result pre="bronchitis virus nucleoprotein localizes to the nucleolus.J Virol2001;75:506â€&quot;12.11119619 81.FriemanMYountBHeiseMKopecky-BrombergSAPalesePBaricRSSevere acute" exact="respiratory" post="syndrome coronavirus ORF6 antagonizes STAT1 function by sequestering nuclear"/>
 <result pre="virus nucleoprotein localizes to the nucleolus.J Virol2001;75:506â€&quot;12.11119619 81.FriemanMYountBHeiseMKopecky-BrombergSAPalesePBaricRSSevere acute respiratory" exact="syndrome" post="coronavirus ORF6 antagonizes STAT1 function by sequestering nuclear import"/>
</results>
